Proteomic and metabolomic characterizations of moyamoya disease patient sera
Abstract Background The pathogenesis of moyamoya disease (MMD) is unclear. Inflammation and immune imbalance have been identified as potential factors contributing to the occurrence and progression of MMD. However, the specific proteins and metabolites responsible for triggering this process are yet...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Brain and Behavior |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/brb3.3328 |
| _version_ | 1797336398362050560 |
|---|---|
| author | Qingbao Guo Qian‐Nan Wang Jingjie Li Simeng Liu Xiaopeng Wang Dan Yu Zheng‐Xing Zou Gan Gao Qian Zhang Fang‐Bin Hao Jie Feng Ri‐Miao Yang Minjie Wang Heguan Fu Xiangyang Bao Lian Duan |
| author_facet | Qingbao Guo Qian‐Nan Wang Jingjie Li Simeng Liu Xiaopeng Wang Dan Yu Zheng‐Xing Zou Gan Gao Qian Zhang Fang‐Bin Hao Jie Feng Ri‐Miao Yang Minjie Wang Heguan Fu Xiangyang Bao Lian Duan |
| author_sort | Qingbao Guo |
| collection | DOAJ |
| description | Abstract Background The pathogenesis of moyamoya disease (MMD) is unclear. Inflammation and immune imbalance have been identified as potential factors contributing to the occurrence and progression of MMD. However, the specific proteins and metabolites responsible for triggering this process are yet to be established. The purpose of this study is to identify differentially expressed proteins and metabolites in patients with MMD and perform Kyoto Encyclopedia of Genes and Genomes pathway integration analysis to pinpoint crucial proteins and metabolites involved in the disease. Methods We performed untargeted metabolomic and data‐independent acquisition proteomic analyses on the serum samples of individuals with MMD and healthy controls (HC). Results In patients with MMD versus HC, 24 proteins and 60 metabolites, including 21 anionic metabolites and 39 cationic metabolites, which were significantly different, were identified. In patients with MMD, several proteins involved in inflammation and immune metabolism, such as tubulin beta‐6 and complement C4, were found to have significantly altered levels. Similarly, many metabolites involved in inflammation and immune metabolisms, such as dimethyl 4‐hydroxyisophthalate, beta‐nicotinamide mononucleotide, 2‐(3‐(4‐pyridyl)‐1H‐1,2,4‐triazol‐5‐yl)pyridine, and PC (17:1/18:2), were significantly altered. Intriguingly, these proteins and metabolites are involved in the progression of atherosclerosis through immune and inflammatory pathways, although some have never been reported in MMD. Moreover, integrated proteomics and metabolomics studies were conducted to determine shared pathways involving cholesterol metabolism, vitamin digestion, fat digestion, and absorption pathways of proteins and metabolites, which warrant further investigation. Conclusions Significant increases in pro‐inflammatory and immunosuppressive abilities have been observed in patients with MMD, accompanied by significant reductions in anti‐inflammatory and immune regulation. Various metabolites and proteins implicated in these processes have been identified for the first time. These findings hold immense significance for comprehending the pathogenesis of MMD and for the development of future drug therapies. |
| first_indexed | 2024-03-08T08:53:50Z |
| format | Article |
| id | doaj.art-d11435508db549c5b856d3ba6a0b616e |
| institution | Directory Open Access Journal |
| issn | 2162-3279 |
| language | English |
| last_indexed | 2024-03-08T08:53:50Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Brain and Behavior |
| spelling | doaj.art-d11435508db549c5b856d3ba6a0b616e2024-02-01T07:45:36ZengWileyBrain and Behavior2162-32792023-12-011312n/an/a10.1002/brb3.3328Proteomic and metabolomic characterizations of moyamoya disease patient seraQingbao Guo0Qian‐Nan Wang1Jingjie Li2Simeng Liu3Xiaopeng Wang4Dan Yu5Zheng‐Xing Zou6Gan Gao7Qian Zhang8Fang‐Bin Hao9Jie Feng10Ri‐Miao Yang11Minjie Wang12Heguan Fu13Xiangyang Bao14Lian Duan15Medical School of Chinese PLA Beijing ChinaDepartment of Neurosurgery, The Eighth Medical Centre Chinese PLA General Hospital Beijing ChinaMedical School of Chinese PLA Beijing ChinaMedical School of Chinese PLA Beijing ChinaMedical School of Chinese PLA Beijing ChinaDepartment of Neurosurgery, The Fifth Medical Centre Chinese PLA General Hospital Beijing ChinaDepartment of Neurosurgery, The Fifth Medical Centre Chinese PLA General Hospital Beijing ChinaMedical School of Chinese PLA Beijing ChinaDepartment of Neurosurgery, The Fifth Medical Centre Chinese PLA General Hospital Beijing ChinaMedical School of Chinese PLA Beijing ChinaDepartment of Neurosurgery, The Fifth Medical Centre Chinese PLA General Hospital Beijing ChinaDepartment of Neurosurgery, The Fifth Medical Centre Chinese PLA General Hospital Beijing ChinaMedical School of Chinese PLA Beijing ChinaDepartment of Neurosurgery, The Fifth Medical Centre Chinese PLA General Hospital Beijing ChinaDepartment of Neurosurgery, The Fifth Medical Centre Chinese PLA General Hospital Beijing ChinaDepartment of Neurosurgery, The First Medical Centre Chinese PLA General Hospital Beijing ChinaAbstract Background The pathogenesis of moyamoya disease (MMD) is unclear. Inflammation and immune imbalance have been identified as potential factors contributing to the occurrence and progression of MMD. However, the specific proteins and metabolites responsible for triggering this process are yet to be established. The purpose of this study is to identify differentially expressed proteins and metabolites in patients with MMD and perform Kyoto Encyclopedia of Genes and Genomes pathway integration analysis to pinpoint crucial proteins and metabolites involved in the disease. Methods We performed untargeted metabolomic and data‐independent acquisition proteomic analyses on the serum samples of individuals with MMD and healthy controls (HC). Results In patients with MMD versus HC, 24 proteins and 60 metabolites, including 21 anionic metabolites and 39 cationic metabolites, which were significantly different, were identified. In patients with MMD, several proteins involved in inflammation and immune metabolism, such as tubulin beta‐6 and complement C4, were found to have significantly altered levels. Similarly, many metabolites involved in inflammation and immune metabolisms, such as dimethyl 4‐hydroxyisophthalate, beta‐nicotinamide mononucleotide, 2‐(3‐(4‐pyridyl)‐1H‐1,2,4‐triazol‐5‐yl)pyridine, and PC (17:1/18:2), were significantly altered. Intriguingly, these proteins and metabolites are involved in the progression of atherosclerosis through immune and inflammatory pathways, although some have never been reported in MMD. Moreover, integrated proteomics and metabolomics studies were conducted to determine shared pathways involving cholesterol metabolism, vitamin digestion, fat digestion, and absorption pathways of proteins and metabolites, which warrant further investigation. Conclusions Significant increases in pro‐inflammatory and immunosuppressive abilities have been observed in patients with MMD, accompanied by significant reductions in anti‐inflammatory and immune regulation. Various metabolites and proteins implicated in these processes have been identified for the first time. These findings hold immense significance for comprehending the pathogenesis of MMD and for the development of future drug therapies.https://doi.org/10.1002/brb3.3328integration analysismetabolomemoyamoya diseaseproteome |
| spellingShingle | Qingbao Guo Qian‐Nan Wang Jingjie Li Simeng Liu Xiaopeng Wang Dan Yu Zheng‐Xing Zou Gan Gao Qian Zhang Fang‐Bin Hao Jie Feng Ri‐Miao Yang Minjie Wang Heguan Fu Xiangyang Bao Lian Duan Proteomic and metabolomic characterizations of moyamoya disease patient sera Brain and Behavior integration analysis metabolome moyamoya disease proteome |
| title | Proteomic and metabolomic characterizations of moyamoya disease patient sera |
| title_full | Proteomic and metabolomic characterizations of moyamoya disease patient sera |
| title_fullStr | Proteomic and metabolomic characterizations of moyamoya disease patient sera |
| title_full_unstemmed | Proteomic and metabolomic characterizations of moyamoya disease patient sera |
| title_short | Proteomic and metabolomic characterizations of moyamoya disease patient sera |
| title_sort | proteomic and metabolomic characterizations of moyamoya disease patient sera |
| topic | integration analysis metabolome moyamoya disease proteome |
| url | https://doi.org/10.1002/brb3.3328 |
| work_keys_str_mv | AT qingbaoguo proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT qiannanwang proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT jingjieli proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT simengliu proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT xiaopengwang proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT danyu proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT zhengxingzou proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT gangao proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT qianzhang proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT fangbinhao proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT jiefeng proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT rimiaoyang proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT minjiewang proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT heguanfu proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT xiangyangbao proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera AT lianduan proteomicandmetabolomiccharacterizationsofmoyamoyadiseasepatientsera |